マーサー・インターナショナルに関するコメント

Upgrades
• $A.O.スミス(AOS.US)$ : Longbow Research Upgrades to Buy from Neutral - PT $71
• $Callon Petroleum(CPE.US)$ : RBC Upgrades to Outperform from Sector Perform - PT $75
• $ダン・アンド・ブラッドストリート・ホールディングス(DNB.US)$ : BofA Securities Upgrades to Neutral from Underperform - PT $17 (from $16)
•$エナンタ・ファーマシューティカルズ(ENTA.US)$ : Evercore ISI Upgrades to Outperform from In Line - PT $62 (from $39)
• $コーニング(GLW.US)$ : CFRA Upgrades to Strong Buy ...

$マーサー・インターナショナル(MERC.US)$ The head of India's leading medical research institute said on Wednesday that Mercer's new oral crown drug molnupiravir has "significant safety issues" that may prevent it from joining the country's list of viral treatments.
The oral drug, molnupiravir, is said to ultimately stop the replication of the virus by introducing a different mechanism in the genetic material, but it could affect growing human cells.